134 related articles for article (PubMed ID: 18246051)
1. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
Bachmann IM; Puntervoll HE; Otte AP; Akslen LA
Mod Pathol; 2008 May; 21(5):583-90. PubMed ID: 18246051
[TBL] [Abstract][Full Text] [Related]
2. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma.
Mihic-Probst D; Kuster A; Kilgus S; Bode-Lesniewska B; Ingold-Heppner B; Leung C; Storz M; Seifert B; Marino S; Schraml P; Dummer R; Moch H
Int J Cancer; 2007 Oct; 121(8):1764-70. PubMed ID: 17597110
[TBL] [Abstract][Full Text] [Related]
3. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
4. Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours.
Häyry V; Tynninen O; Haapasalo HK; Wölfer J; Paulus W; Hasselblatt M; Sariola H; Paetau A; Sarna S; Niemelä M; Wartiovaara K; Nupponen NN
Neuropathol Appl Neurobiol; 2008 Oct; 34(5):555-63. PubMed ID: 18346113
[TBL] [Abstract][Full Text] [Related]
5. Expression of polycomb group protein EZH2 in nevi and melanoma.
McHugh JB; Fullen DR; Ma L; Kleer CG; Su LD
J Cutan Pathol; 2007 Aug; 34(8):597-600. PubMed ID: 17640228
[TBL] [Abstract][Full Text] [Related]
6. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.
Sparrow LE; Eldon MJ; English DR; Heenan PJ
Am J Dermatopathol; 1998 Jun; 20(3):255-61. PubMed ID: 9650698
[TBL] [Abstract][Full Text] [Related]
7. Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression.
Xu XZ; Garcia MV; Li TY; Khor LY; Gajapathy RS; Spittle C; Weed S; Lessin SR; Wu H
Mod Pathol; 2010 Feb; 23(2):187-96. PubMed ID: 19898426
[TBL] [Abstract][Full Text] [Related]
8. IMP-3 is a novel progression marker in malignant melanoma.
Pryor JG; Bourne PA; Yang Q; Spaulding BO; Scott GA; Xu H
Mod Pathol; 2008 Apr; 21(4):431-7. PubMed ID: 18204432
[TBL] [Abstract][Full Text] [Related]
9. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma.
Wang H; Pan K; Zhang HK; Weng DS; Zhou J; Li JJ; Huang W; Song HF; Chen MS; Xia JC
J Cancer Res Clin Oncol; 2008 May; 134(5):535-41. PubMed ID: 17917742
[TBL] [Abstract][Full Text] [Related]
10. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
11. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
[TBL] [Abstract][Full Text] [Related]
12. Nestin expression is associated with aggressive cutaneous melanoma of the nodular type.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
Mod Pathol; 2014 Mar; 27(3):396-401. PubMed ID: 24030749
[TBL] [Abstract][Full Text] [Related]
13. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions.
Breuer RH; Snijders PJ; Sutedja GT; Sewalt RG; Otte AP; Postmus PE; Meijer CJ; Raaphorst FM; Smit EF
Lung Cancer; 2005 Jun; 48(3):299-306. PubMed ID: 15892997
[TBL] [Abstract][Full Text] [Related]
14. WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis.
Garrido-Ruiz MC; Rodriguez-Pinilla SM; Pérez-Gómez B; Rodriguez-Peralto JL
J Cutan Pathol; 2010 May; 37(5):542-8. PubMed ID: 19638168
[TBL] [Abstract][Full Text] [Related]
15. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.
Nodin B; Fridberg M; Jonsson L; Bergman J; Uhlén M; Jirström K
Diagn Pathol; 2012 Jul; 7():82. PubMed ID: 22805320
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.
Slipicevic A; Holm R; Emilsen E; Ree Rosnes AK; Welch DR; Mælandsmo GM; Flørenes VA
BMC Cancer; 2012 Feb; 12():73. PubMed ID: 22356677
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry of p16 in nevi of pregnancy and nevoid melanomas.
Koh SS; Roehmholdt BF; Cassarino DS
J Cutan Pathol; 2018 Dec; 45(12):891-896. PubMed ID: 30178478
[TBL] [Abstract][Full Text] [Related]
18. Expression of the ets-1 proto-oncogene in melanocytic lesions.
Keehn CA; Smoller BR; Morgan MB
Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
[TBL] [Abstract][Full Text] [Related]
19. DEK expression in melanocytic lesions.
Kappes F; Khodadoust MS; Yu L; Kim DS; Fullen DR; Markovitz DM; Ma L
Hum Pathol; 2011 Jul; 42(7):932-8. PubMed ID: 21316078
[TBL] [Abstract][Full Text] [Related]
20. Progression-related expression of beta3 integrin in melanomas and nevi.
Van Belle PA; Elenitsas R; Satyamoorthy K; Wolfe JT; Guerry D; Schuchter L; Van Belle TJ; Albelda S; Tahin P; Herlyn M; Elder DE
Hum Pathol; 1999 May; 30(5):562-7. PubMed ID: 10333228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
